E Fund Management’s Myriad Genetics MYGN Stock Holding History

E Fund Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.5K	Sell	11,819 -2,890	-20%	-$13.1K	﹤0.01%	482
2026 Q1	$66.2K	Buy	+14,709	New	+$76.6K	﹤0.01%	482
2025 Q2	$66.8K	Sell	12,575 -1,145	-8%	-$6.76K	﹤0.01%	386
2025 Q1	$122K	Buy	13,720 +1,968	+17%	+$23.6K	0.01%	378
2024 Q4	$161K	Buy	+11,752	New	+$217K	0.01%	372
2024 Q2	–	Sell	-11,776	Closed	-$251K	–	355
2024 Q1	$251K	Buy	+11,776	New	+$253K	0.02%	299
2023 Q4	–	Sell	-10,709	Closed	-$172K	–	322
2023 Q3	$172K	Buy	10,709 +159	+2%	+$3.03K	0.01%	265
2023 Q2	$245K	Buy	10,550 +911	+9%	+$19.9K	0.02%	248
2023 Q1	$224K	Sell	9,639 -1,183	-11%	-$24K	0.02%	279
2022 Q4	$157K	Sell	10,822 -961	-8%	-$17.9K	0.01%	314
2022 Q3	$225K	Sell	11,783 -698	-6%	-$16K	0.02%	283
2022 Q2	$227K	Buy	+12,481	New	+$259K	0.02%	278

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

E Fund Management's MYGN Position: Q2 2026 in Review

E Fund Management reduced its Myriad Genetics (MYGN) stake by 20% in Q2 2026, selling an estimated $13.1K and leaving 11,819 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

E Fund Management first reported a position in MYGN in Q2 2022 and has held it in 12 quarters since. The position peaked at $251K in Q1 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

E Fund Management held 11,819 shares of Myriad Genetics worth $67.5K as of Q2 2026.
E Fund Management sold 2,890 Myriad Genetics shares in Q2 2026, an estimated $13.1K.
Myriad Genetics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #482 holding.
E Fund Management first reported a position in Myriad Genetics in Q2 2022 and has held it in 12 quarters since.
E Fund Management's Myriad Genetics position peaked at $251K in Q1 2024.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.